Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

Anti-CD19 CAR-T cell therapy is effective in B-cell lymphoma. However, it is rarely used in lymphoma combined with other malignant tumours.

CASE DESCRIPTION:

A relapsed/refractory follicular lymphoma (r/r FL) patient underwent anti-CD19 CAR-T cell therapy and achieved complete response to lymphoma. However, gastric adenocarcinoma (GAC) was diagnosed during the cellular therapy. After infusion of CAR-T cells, he received curative treatment for GAC, and maitained complete response in both r/r FL and GAC after the treatment.

WHAT IS NEW AND CONCLUSION:

Anti-CD19 CAR-T therapy is an effective treatment for r/r FL, also provided opportunity for the sequential therapy of GAC, and remained significant quality of life afterwards.

• Authors: Jiaxin Liu, Fang Cao, Zhemin Li, Hongye Gao, Chen Zhang, Tingting Du, Ziyu Li, Yuqin Song, Jun Zhu, Zhitao Ying
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 47 Issue 9 Pg. 1466-1470 (Sep 2022) ISSN: 1365-2710 [Electronic] England
• PMID: 35437775 (Publication Type: Case Reports, Review)
• Copyright: © 2022 John Wiley & Sons Ltd.

Chemical References

• Antigens, CD19
• Receptors, Chimeric Antigen

Topics

• Adenocarcinoma (therapy)
• Antigens, CD19
• Humans
• Lymphoma, Follicular (therapy)
• Male
• Quality of Life
• Receptors, Chimeric Antigen
• Stomach Neoplasms (therapy)
• T-Lymphocytes